Market Overview

Benzinga's Top #PreMarket Losers


Athersys (NASDAQ: ATHX) dropped 52.38% to $1.30 in pre-market trading on failed trial results for ulcerative colitis.

OncoGenex Pharmaceuticals (NASDAQ: OGXI) shares fell 47.84% to $5.06 in pre-market trading after the company and Teva Pharmaceutical Industries (NYSE: TEVA) offered top-line survival results of the Phase III SYNERGY trial for combo with first-line docetaxel/prednisone therapy.

POZEN (NASDAQ: POZN) shares dropped 18.84% to $7.41 in pre-market trading following Friday's Complete Response Letter from the FDA.

Newmont Mining (NYSE: NEM) dipped 5.29% to $25.05 in pre-market trading after the company terminated its merger talks with Barrick Gold (NYSE: ABX).

Posted-In: Premarket MoversNews Movers & Shakers Pre-Market Outlook Markets


Related Articles (ATHX + ABX)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

AMAG Pharma Announces Publication of Data from Trial of MuGard in the Journal Cancer

UPDATE: Organovo Reports Pre-Release Availability of 3D Liver Contract Services